Suggested remit - To appraise the clinical and cost effectiveness of patiromer within its marketing authorisation for treating hyperkalaemia.
Status In progress
Process STA pre-2018
ID number 877

Provisional Schedule

Expected publication 05 February 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence


Companies sponsors Vifor Pharma
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Care UK
  Pumping Marvellous Foundation
Professional groups British Society for Heart Failure
  The Renal Association
  Royal College of Pathologists
  Royal College of Physicians
  UK Renal Pharmacy Group


Comparator companies none
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
29 October 2019 Committee meeting: 2
26 November 2018 The next committee meeting for this appraisal will be rescheduled. This is to enable critique of additional evidence submitted by the company following ACD consultation.
29 October 2018 - 19 November 2018 Appraisal consultation
03 October 2018 Committee meeting: 1
09 May 2018 Invitation to participate
11 January 2018 (00:00) Scoping workshop
21 November 2017 - 19 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
21 November 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance